ISPC vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ISPC vs JNJ: Head-to-Head Comparison
This page compares iSpecimen Inc. (ISPC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.